Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antiparkinsonian drugs: pharmacological and therapeutic aspects.

× No keyword cloud information.

66 in total

1. The distribution of acetylcholinesterase and butyryl-cholinesterase in the human brain.

Authors: F F FOLDES; E K ZSIGMOND; V M FOLDES; E G ERDOS
Journal: J Neurochem Date: 1962 Nov-Dec Impact factor: 5.372

2. Corticosteroid and growth hormone secretion in patients treated with L-dopa.

Authors: K von Werder; G R van Loon; F Yatsu; P H Forsham
Journal: Klin Wochenschr Date: 1970-12-15

Review 3. Theoretical implications of the use of L-dopa in parkinsonism. A review.

Authors: H Klawans; M M Ilahi; D Shenker
Journal: Acta Neurol Scand Date: 1970 Impact factor: 3.209

4. Striatal amines, experimental tremor and the effect of harmaline in the monkey.

Authors: L J Poirier; T L Sourkes; G Bouvier; R Boucher; S Carabin
Journal: Brain Date: 1966-03 Impact factor: 13.501

5. Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays.

Authors: J P Morgan; J R Bianchine; H E Spiegel; L Rivera-Calimlim; R M Hersey
Journal: Arch Neurol Date: 1971-07

6. L-dihydroxyphenylalanine: effect on S-adenosylmethionine in brain.

Authors: R J Wurtman; S Matthysse; J Stephenson; R Baldessarini
Journal: Science Date: 1970-07-24 Impact factor: 47.728

7. Stimulation of human-growth-hormone secretion by L-dopa.

Authors: A E Boyd; H E Lebovitz; J B Pfeiffer
Journal: N Engl J Med Date: 1970-12-24 Impact factor: 91.245

8. The role of biogenic amines in the extra-pyramidal system.

Authors: A M Ernst
Journal: Acta Physiol Pharmacol Neerl Date: 1969-06

9. Parkinsonism: onset, progression and mortality.

Authors: M M Hoehn; M D Yahr
Journal: Neurology Date: 1967-05 Impact factor: 9.910

Review 10. Dopamine (3-hydroxytyramine) and brain function.

Authors: O Hornykiewicz
Journal: Pharmacol Rev Date: 1966-06 Impact factor: 25.468

7 in total

1. Effect of levodopa on the human pattern electroretinogram and pattern visual evoked potentials.

Authors: I Gottlob; H Weghaupt; C Vass; E Auff
Journal: Graefes Arch Clin Exp Ophthalmol Date: 1989 Impact factor: 3.117

2. Inhibition of the apomorphine gnawing compulsion by amantadine.

Authors: R Hackman; P Pentikainen; P J Neuvonen; H Vapaatalo
Journal: Experientia Date: 1973-12

3. Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease.

Authors: J R Bianchine; L Sunyapridakul
Journal: Drugs Date: 1973 Impact factor: 9.546

4. Amphetamines in the treatment of Parkinson's disease.

Authors: J D Parkes; D Tarsy; C D Marsden; K T Bovill; J A Phipps; P Rose; P Asselman
Journal: J Neurol Neurosurg Psychiatry Date: 1975-03 Impact factor: 10.154

5. [HGH secretion after oral application of L-dopa and L-carbidopa (author's transl)].

Authors: W Schönberger; R Ziegler; B Brodt; W Grimm
Journal: Eur J Pediatr Date: 1976-06-08 Impact factor: 3.183

6. Effect of levodopa on the human dark adaptation threshold.

Authors: I Gottlob; K Strenn; B Schneider
Journal: Graefes Arch Clin Exp Ophthalmol Date: 1994-10 Impact factor: 3.117

Review 7. Exosomes in Parkinson: Revisiting Their Pathologic Role and Potential Applications.

Authors: Yassamine Ouerdane; Mohamed Y Hassaballah; Abdalrazeq Nagah; Tarek M Ibrahim; Hosny A H Mohamed; Areej El-Baz; Mohamed S Attia
Journal: Pharmaceuticals (Basel) Date: 2022-01-07

7 in total